Short answer
Adicet Bio Inc (ACET) filed an 8-K current report with the SEC on September 1, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Adicet completed the last patient visit for planned prula-cel analysis in systemic lupus erythematosus.
Adicet Bio Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Adicet completed the last patient visit for planned prula-cel analysis in systemic lupus erythematosus
- Study includes patients with and without lupus nephritis
- Upcoming analysis represents a clinical catalyst for prula-cel, formerly ADI-001
- Corporate update details available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Prula-cel SLE/LN analysis completed, covering 22 patients with minimum 6-month follow-up and 13 with at least 12 months
- Topline prula-cel data expected September 2026, the key near-term catalyst for efficacy, safety and potential pivotal-trial planning
- FDA cleared ADI-212 IND for mCRPC, with Phase 1 enrollment targeted for 4Q 2026
- Outpatient prula-cel administration expanded following FDA alignment, potentially improving trial execution and treatment scalability
- First in vivo CAR-T candidate expected to enter clinical development in 2H 2027, extending the company’s longer-term pipeline beyond cell therapy programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adicet Bio Inc 8-K filings
Get the next ACET 8-K as it lands
Follow ACET for push alerts, or ask the research agent what this filing means.